The Laboratoire National de Contrôle des Produits Pharmaceutiques was established back in 1995 as Algeria’s pharmaceuticals regulator with a view to managing the circulation of medicines within the country. It has subsequently been warded the status of reference laboratory by the World Health Organisation (WHO).
Contact address: Lot Geraud petit staouali, Dely Brahim, Alger, Algerie
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Sabrina Chan, Senior Executive at HKAPI, highlights progress in Hong Kong’s biomedical ambitions, including establishing an independent regulator, expanding clinical trial capacity via the Greater Bay Area Clinical Trial Institute…
As Abu Dhabi translates strategy into execution, the focus turns from platform design to operational delivery. Albarah Elkhani, COO of Integrated Health Solutions at M42, details how large-scale genomics, clinical…
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
Sabrina Zimmerman, General Manager for Taiwan, Hong Kong, and Macau and APAC (excluding Japan) Portfolio Head at Biogen, shares her perspective on the company’s expanding presence in Asia and its…
Taiwan’s clinical research ecosystem has evolved rapidly in recent years, reflecting Asia’s growing role in global drug development. Samuel Su, Founder and CEO of Bestat Pharmaservices, discusses how the organisation…
After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable…
Craig Martin, CEO of the Orphan Therapeutics Accelerator (OTXL), discusses the urgent need for a new business model to rescue abandoned clinical-stage programs in the rare disease sector. He details…
Dr Chen-Yu Cheng, founder and chairman at Formosa Laboratories & Pharmaceuticals, is leading a strategic transition from generic API manufacturing toward high- value CDMO services and innovative drug development. By…
Asia is emerging as a critical frontier in oncology research, yet much of global drug development continues to overlook the region’s specific clinical needs. At the National Cancer Center Japan,…
Christine Baeder, President of USA and LATAM at Apotex, discusses the company’s evolution following private equity investment, its Generics Plus strategy, and the critical role of the US market. She…
Dr Cyrus Yang, CEO of Taiwan Bio Therapeutics, outlines how he transformed the company – founded in 2014 with proprietary MSC‑expansion technology – into a global innovator in cell and gene therapy.…
Healthcare systems across the world continue to struggle with fragmentation, rising costs and reactive models of care that intervene too late. Dimitris Moulavasilis, Group CEO of M42, outlines how an…
Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Kim Moran, SVP & Head of US Rare Disease at UCB, discusses how the company is building on its long-standing heritage in neurology to expand into rare and ultra-rare conditions.…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
Nasha Fitter, a tech entrepreneur and CEO of the FOXG1 Research Foundation, discusses the radical shift in drug development led by a new generation of sophisticated parent-entrepreneurs. Following her daughter’s…
Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class…
Siegfried Gschliesser, co-founder and CEO of Anya Biopharm, has spent over two decades shaping the pharmaceutical landscape in Asia. Under his guidance, Anya has pioneered a proprietary oral peptide delivery platform,…
Boston Scientific’s Dan Silver reflects on his global leadership journey and the evolution of the company’s presence in one of Asia’s most advanced healthcare systems. Silver discusses Boston Scientific’s growth…
Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape.…
Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle,…
Bringing together clinical scale, academic depth, and a strong engineering mindset, China Medical University Hospital has positioned itself as more than a care provider. In this interview, Dr Der-Yang Cho,…
For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward…
See our Cookie Privacy Policy Here
